Latest revision as of 22:35, 22 November 2017

Aim

In constructing the sequence of a single chain insulin we had to ensure that our sequence was not under any existing patents so that we could submit our sequence into the Open Source iGEM registry. With a bit of help from Maxwell Lawyers we went through several single chain insulin patents, method patents and existing patents for current insulin dispensing devices/therapeutics using the FDA orange book. The goal was to make sure our work did not come under any existing patents so we would not infringe any ownership rights.

Importantly, we recognise the difficulty of being thorough with all existing patents and the content provided is not intended to be legal advice and should not be used as such. To determine whether you are infringing a patent; the best course of action is to seek a qualified patent lawyer.

To examine the way we approached patents - please click on the links below for easy navigation to each section.

How to read a patent

After our chat with Uppsala (check it out in collaborations), our team realised that patents are a very poorly understood area, particularly for young aspiring scientists with new and challenging ideas.

With a resident legal student in our team - we created a quick checklist on How to read a patent

KEY CONSIDERATIONS

1. Patents give an exclusive commercial right to the invention aka. a monopoly

2. The "claims" of a patent, detail what is covered by the patent.

3. If it is NOT in the patent; it is NOT patentable.

And it is with this checklist that we approached the analysis of a wide range of patents below.

1. Single Chain Insulin Patents

Although our team attempted to be thorough, we recognise that not all patents can be checked. However, we targeted patents with the greatest relevance to avoid legal suits that may arise. Our primary concern was single chain insulin patents since they have only been recently explored in greater depth and quoted to have benefits like enhanced thermostability. As these single chain insulins are likely to be the next insulin product in the market, we wanted to create one, outside the scope of existing patents, to characterise and compare our product.

Importantly there is an exception in patents for research purposes. This means that if the work you performed is for research purposes only, you do not infringe the relevant patent. You cannot however, submit the part into the open source registry or try and commercialise it. As we are submitting 'Winsulin,' our single chain insulin, it must not be patented.

HELP RUBY HELP RUBY HELP RUBY

.

DIMARCHI ET AL.

Single Chain Insulin with high bioactivity

Patent No: US 9458,220 B2

October 4^th 2016

CLAIM

COMPARISON WITH OUR SEQUENCE

Y/N

A single chain insulin agonist analogue with stricture of B-LM-A wherein B represents an insulin B chain comprising the sequence R₂₂X₂₅LCGX₂₉_… and A represents an insulin A chain comprising the sequence

GIVX₄X₅CCX₈_…-R₁₃

Both insulin A and B chains involve R groups which stand for modifications eg. carboxylation. As our insulin B chain does not contain any modifications (except for a substituted glycine on the A chain), our construct is outside the patent

N

Furthermore the linking moiety linking the carboxy terminus of the B chain to the amino terminus of the A chain; further wherein the linking moiety is an 8 amino acid sequence comprising of the sequence X₅₁X₅₂GSSSX₅₇X₅₈ wherein

X₅₁ = group consisting of glycine, alanine, valine, leucine, isoleucine, isoleucine and ornithine

X₅₂ = any amino acid other than tyrosine

X₅₇ and X₅₈ are independently selected form the ground consisting of arginine, lysine and ornithine

Our amino acid sequence is squarely outside the scope of 8 amino acids.

Even if we did fall within the claim; we do not contain the 8 amino acid sequence using both potential orientations

X₅₁ is glutamine or arginine in our sequence

B-chain – QR . . . KR – A-chain

N

The LM also requires the sequence of GAGSSSRR or a sequence that differs from GAGSSRR by 1 or 2 amino acids

Our sequence is 12 amino acids long and differs by more than 4 amino acids.

N

LM represents linking moiety linking the carboxyl terminus of the B chain to the amino terminus of the a chain, wherein said linking moiety is an 8 amino acid sequence consisting of X₅₁X₅₂X₅₃X₅₄... wherein X₅₁ is selected from the group consisting of glycine, alanine, valine, leucine, isoleucine and proline…

Similarly, the patent claim is over an 8 amino acid sequence. Applying the same principle our;

X₅₁ is glutamine or arginine (depending on orientation) and outside the scope

N

LEE ET AL.

Single Chain Insulin Analog and a polynucleotide sequence encoding the analog

Patent No: US 6,630,348 B1

October 7^th 2003

CLAIM

COMPARISON WITH OUR SEQUENCE

Y/N

A single chain insulin analogue compound of formula (I) having the properties of greater insulin receptor binding activity than proinsulin and less insulin receptor binding activity than insulin:

B chain - X – A chain wherein:

General B – X – A chain single chain formula

Y

B and A chain are human insulin chains, respectively and,

Our B and A chain are human insulin chains although our A chain includes a modification (A21 substitution into glycine)

N

X is a joining peptide of about 5 to 18 amino acids comprising the following sequence: Gly-Gly-Gly-Pro-Gly- Lys-Arg

Where the term ‘comprising’ is included, the patent requires that the specific sequence named MUST be part of the linker region.

Although our sequence is 12 amino acids long, it does not contain the ‘GGGPGLR’ identified in the patent

N

LEE ET AL.

Single Chain Insulin Analogs

Patent No: EP 1 193 272 B1

October 30^th 2004

CLAIM

COMPARISON WITH OUR SEQUENCE

Y/N

A single chain insulin analogue compound of formula (I) having the properties of greater insulin receptor binding activity than prosinsulin and less insulin receptor binding activity than insulin:

B Chain – U_I – Z_n – Y – Z_I – U_n– A chain

B and A chain are human insulin chains respectively and

We have a modified A chain

N

U is an arginine or lysine residue

Our ‘U’ is glutamine

N

Z is a glycine

Z Is Glycine

Y

I is an integer of 2 – n

N is an integer of 0 or 2 and

The maximum size of the linker sequence when considering this is 9 amino acids. Since our sequence is 12 amino acids they are outside the scope

N

Y is glycine-proline-glycine, or alanine-proline-glycine-aspartic acid–valine, or tyrosine-proline-glycine-aspartic acid-valine, or histidine-proline-glycine-aspartic acid-valine.

Our sequence has no proline

N

KJELDSEN ET AL.

Single Chain insulin

Patent No: EP 1692168 B1

December 3^rd, 2004

CLAIM	COMPARISON WITH OUR SEQUENCE	Y/N
Single-chain insulin for treatment of type 1 diabetes and type 2 diabetes having the formula B(1-26)- X₁ - X₂ - X₃- X₄- A (1-21),	B - linker - A formula	Y
B(1-26) is a peptide chain consisting of the first 26 amino acid residues of the B chain of human insulin counted from the N-terminal end of the B chain or an analogue of the B-chain with one addition or one deletion of one of the amino acid residues in the B-chain or derivative of the B-chain being chemically modified by introducing a group in the side chain in one or more positions of the B-chain or by oxidation or reduction of the side chains of the amino acids residues in the B-chain,	Our B chain consists of 28 AA. Although the patents contain different versions eg ‘an analogue of the B-chain with one addition or deletion’ – the total length of the B-chain must STILL be 26AA.	N
and A(1-21) is the natural insulin A chain or an analogue thereof with one addition or one deletion of one of the amino acid residues in the A-chain or derivative of the A-chain being chemically modified by introducing a group in the side chain in one or more positions of the A-chain or by oxidation or reduction of the side chains of the amino acids residues in the A-chain, wherein	In our sequence construct – the A chain is 21 amino acid however it is a modification of the natural protein. It does not fall within an 'analogue' as there is no complete addition/deletion of an amino acid.	N
X₄does not contain two adjacent basic amino acid residues and wherein the single-chain insulin has an affinity to the human insulin receptor of at least about 20% of that of human insulin if the single-chain insulin molecule is not chemically modified by acylation.	We have 2 adjacent basic amino acid residues and the affinity cannot be tested	N
wherein X₁ is Thr, Lys or Arg	X₁ is glutamine	N
X₂ is Pro, Lys or Asp,	X₂is arginine	N
X₃ is Lys, Pro or Glu,	X₃ is glycine	N
X₄ is a peptide sequence with the following formula X_a-X_b-X_c-X_d-X_e-X_fX_g (SEQ ID NO:129) wherein X_a is selected from the group consisting of L, R, T, A, H, Q, G, S and V; X_b is selected from the group consisting of W, G, S, A, H, R, and T; X_c is selected from the group consisting of L, Y, M, H, R, T, Q, K, V, S, A, G and P; X_d is selected from the group consisting of R, A, Y, M, S, N, H, and G; X_e is selected from the group consisting of S, R, A, T, K, P, N, M, H, Q, V, and G; X_f is selected from the group consisting of G and A; and X_g is selected from the group consisting of K, R, P, H, F, T, I, Q, W, and A,	The total linker length that can be formulated from X_a– X_g is 7 amino acids with the three other residues for X₁ – X₃. This totals to a maximum linker length of 10 amino acids. Our linker is 12 amino acids long.	N

WEISS ET AL.

Fibrillation-resistant insulin and insulin analogues

Patent No:EP 2074140 B1

April 6th, 2009

CLAIM	COMPARISON WITH OUR SEQUENCE	Y/N
An insulin analogue comprising a single chain polypeptide containing an insulin A-chain polypeptide and an insulin B-chain polypeptide connected by a truncated linker,	Our linker is truncated from the entire C-peptide to 12 amino acids and has the general formula of B-X-A where our linker is QRGGGSGGGQKR	Y
wherein the truncated linker is a polypeptide selected from the group consisting of:		Y
a polypeptide having the sequence GGGPRR	No proline	N
a polypeptide having the sequence GGPRR	No proline	N
a polypeptide having the sequence GSEQRR	No glutamate	N
a polypeptide having the sequence RREQR	No glutamate	N
a polypeptide having the sequence RREALQKR	No glutamate	N
a polypeptide having the sequence GAGPRR	No proline	N
a polypeptide having the sequence GPRR	No proline	N
wherein the insulin B-chain polypeptide optionally contains one or more of: an aspartate substitution at the position corresponding to position B10 of insulin, a lysine or an aspartate substitution at the position corresponding to position B28 of insulin, and a proline substitution at the position corresponding to position B29 of insulin	Our B-chain is native human insulin	N
and wherein the insulin A-chain polypeptide contains a histidine substitution at the position corresponding to position A8 of insulin.	Our A-chain does not contain the relevant substitution	N

STOWELL ET AL.

Chemically and thermodynamically stable insulin analogues and improved

methods for their production

Patent No: US 9006176 B2

October 16^th 2012

CLAIM

COMPARISON WITH OUR SEQUENCE

Y/N

A single chain insulin (SCI) compound of formula a(I):

B chain - C’ – A Chain (Formula (I))

having the properties of higher affinity for the insulin receptor and lower affinity for the IGF-1 receptor as compared to those of native proinsulin with chemical and thermodynamic degradation profiles such that the SCI can be formulated and stored for extended periods of time without refrigeration;

Correct linker formulation of B-linker-A

Y

W herein B chain and A chain are modified human insulin chains; and

Only the A chain is modified

N

Wherein C’ covalently links the C-terminus of the B chain to the N-terminus of the A chain, and is a peptide of 5 amino acids comprising the following sequence: Y-P-G-D-X (SEQ ID NO: 1); wherein X is any amino acid;

No proline (P) and no aspartic acid (D)

N

wherein the B chain is modified from a native human insulin B chain (SEQ ID NO:11), and A chain is modified from a native human insulin A chain (SEQ ID NO:10), wherein the modifications comprise one or more mutations at

(1) Gln5, Gln15, Asn18, or Asn21 of SEQ ID NO:10, or

(2) Asn3 or Gln5 of SEQ ID NO:11; resulting in enhanced resistance to deamidation.

B is not modified and A chain does not have similar modifications, rather an addition at residue 1 without the purpose of resisting deamination.

N

2. Method Patents

In looking at patents, we first considered looking at different methods of production – particularly whether or not Bacillus secretory methods are patented for insulin production.

From a preliminary search, Bacillus secretion has been previously patented however most are now expired. If it is possible to find a patent using the same method of production as a previously patented product, it will not infringe anyone elses intellectual property.

relatively important PATENT STUFF

STAHL ET AL.

Method for Producing Heterologous Proteins

Patent No: US4801536A

November 10th, 1985

STAHL ET AL.

CLAIMS	COMPARISON WITH OUR METHOD	Y/N
Status: EXPIRED. Now this patent has expired. Importantly – it covers our project as we have a heterologous protein being attached via a secretion tag to the actual plasmid vector design.		Y
A method for producing a heterologous protein in a bacterial host cell such that the protein is exported from the host cell into the culture medium, the method comprising culturing in a bacterial culture medium a genetically engineered bacterial strain containing a fusion DNA sequence which comprises a first nucleotide sequence encoding at least an N-terminal portion of a flagellin protein native to the bacterial host cell species and a second nucleotide sequence encoding the heterologous protein, said first nucleotide sequence being linked via its 3' terminus to the 5' terminus of the second DNA sequence and said fusion DNA sequence being operatively linked to an expression control sequence and wherein said N-terminal portion results in the export of said heterologous protein.	Our plasmid falls directly into this means of production. As this patent has since expired and we fall under it – the methods that are encoded are free to be used and thus not for law suit.	Y
A plasmid as identified in any of Tables 2 to 5 of the specification by the designation pSPA or pSPB.	WB800 plasmid	N
A DNA sequence flanked by and in proper reading frame with a non-wild type open reading frame encoding a secretory signal sequence having the amino acid sequence: pSPB4, pSPB9, pSPB19, pSPB20, pSPB23, pSPB28	None of the plasmids mentioned are being used nor are the AA sequences that are described in greater detail in the patent	N

KOVACEVIC ET AL.

Method for expression and secretion in Bacillus

Patent No: US5032510A

July 16th, 1991

CLAIMS

COMPARISON WITH OUR METHOD

Y/N

STATUS: Expired. The invention method claimed is now open source.

Y

1. A method for expressing a peptide in Bacillus, said method comprising

We are expressing a peptide/polypeptide in Bacillus

Y

a) transforming a Bacillus host cell which is rendered competent for transformation with a recombinant DNA expression vector which is selectable and capable of replication in said host cell, said vector comprising

Our Bacillus host cell was made competent specifically for recombinant DNA uptake. The expression vector is also capable of replication

Y

1) the transcriptional and translational activating sequence of the Staphylococcus aureus nuclease gene and

2) a cloned DNA sequence that codes for a polypeptide, and

This vector however does not include a Staph. Aureus nuclease gene.

Winsulin is a single poly-peptide chain, while Insulin is a dual-peptide complex

N

b) culturing said transformed cell under conditions suitable for expression of said polypeptide, subject to the limitation 1) that said cloned DNA sequence that codes for said polypeptide and said transcriptional and translational activating sequence are immediately adjacent, in translational reading frame and positioned for expression of said polypeptide and 2) that said cloned DNA sequence that codes for said polypeptide is exclusive of the nucleotide triplet that codes for the N-terminal amino acid of said polypeptide when said amino acid is methionine.

This potentially could be an issue, depending on the reading and interpretation. However, since we fall outside of the above key aspects of this individual claim, we are still in the clear.

N

BERKA ET AL.

Heterologous polypeptide expressed in filamentous fungi, processes for their preparation, and vectors for their preparation

Patent No: EP0369817B1

April 24th, 1996

CLAIMS

COMPARISON WITH OUR METHOD

Y/N

Status: EXPIRED

The expiry date of this patent is extremely critical as it patents the production of proteins in a Bacillus cell with multiple gene knockouts. Importantly, the strain used by us, WB800 contains 8 protease knockouts and thus falls within the scope of this patent. As the patent has expired –this means of production is available for use.

Y

Claim 1

A Bacillus cell characterised in containing a mutation in the epr gene, said epr gene encoding a protein comprising the amino acid sequence of Figure 6 or an evolutionary homologue thereof of other Bacillus species, having protease activity, said mutation resulting in inhibition of the production by said cell of proteolytically active epr gene product.

We have a mutation in the epr gene in WB800, which renders the EPR protein inactive such that it does not have a proteolytically active epr gene product

Y

Claim 16

A method for producing a heterologous polypeptide in a Bacillus cell, characterised in comprising: introducing into said cell a gene encoding said heterologous polypeptide, modified to be expressed in said cell, said Bacillus cell containing mutations in the apr and npr genes, and further containing mutations in one or more of the genes encoding the Epr protease, RP-I, or RP-II, said Epr, RP-I and RP-II comprising the amino acid sequences set out in Figures 6, 10 and 14 respectively, or evolutionary homologues thereof of other Bacillus species, having protease activity, wherein said mutation results in the inhibition of the production by said cell of proteolytically active Epr protease, RP-I or RP-II.

We have a mutation in aprE and nprE and also epr and thus fall within this claim.

Y

WIDNER ET AL.

Methods for producing a polypeptide in a Bacillus cell

Patent No: US6255076B1

July 3rd, 2001

CLAIMS

COMPARISON WITH OUR METHOD

Y/N

1. A method for producing a polypeptide, comprising:

2.

(a) cultivating a Bacillus cell in a medium conducive for the production of the polypeptide, wherein the Bacillus cell comprises a nucleic acid construct comprising a tandem promoter in which each promoter sequence of the tandem promoter is operably linked to a nucleic acid sequence encoding the polypeptide, wherein the tandem promoter comprises promoters selected from the group consisting of the amyL promoter, amyQ promoter, aprH promoter, cryIIIA promoter, subtilisin Carlsberg gene promoter, and consensus promoters of the amyL promoter, amyQ promoter, aprH promoter, cryIIIA promoter, and subtilisin Carlsberg gene promoter having the sequence TTGACA for the “_35” region and TATAAT for the “_10” region; and

(b) isolating the polypeptide from the cultivation medium.

We do not have a tandem promoter series, therefore we fall outside of this claim.

We are also using the … promoter, which is not listed there.

We will be cultivating the medium for polypeptide isolation however.

N

11. A method for producing a polypeptide, comprising:

(a) cultivating a Bacillus cell in a medium conducive for the production of the polypeptide, wherein the Bacillus cell comprises a nucleic acid construct comprising

(i) a consensus promoter obtained from Bacillus amyloliquefaciens alpha-amylase gene (amy Q) or Bacillus subtilis alpha-amylase gene (amy E) having the sequence TTGACA for the “_35” region and TATAAT for the “_10” region operably linked to a single copy of a nucleic acid sequence encoding the polypeptide and

(ii) an mRNA processing/stabilizing sequence located downstream of the consensus promoter and upstream of the nucleic acid sequence encoding the polypeptide; and

(b) isolating the polypeptide from the cultivation medium.

Arguable – how to define whether the medium we will use will be ‘conductive’ or not is vague.

We are not using a consensus promoter from Bacillus amyloliquefaciens, but are using the Bacillus subtilis strain. The promoter we have selected is p-Spac

We also do not have an mRNA processing or stabilising sequence in our gblock.

We are isolating our polypeptide from the cultivation medium.

N

BEDZYK ET AL.

Natural promoters for gene expression and metabolic monitoring in Bacillus species

Patent No: EP1294909 A2

June 29th, 2001

CLAIMS

COMPARISON WITH OUR METHOD

Y/N

Legal Status: abandoned patent

Once a patent is abandoned it does not have any effect.

N

A method for the expression of a coding region of interest in a Bacillus sp comprising:

a) providing a transformed Bacillus sp cell having a chimeric gene comprising a nucleic acid fragment comprising the promoter region of a Bacillus gene operably linked to a coding region of interest expressible in a Bacillus sp, wherein the nucleic acid fragment comprising the promoter region of a Bacillus gene is selected from the group consisting of narGHJT, csn, yncM, yvyD, yvaWXY, ydjL, sunA, and yolIJK and homologues thereof; and

b) growing the transformed Bacillus sp cell of step (a) in the absence of oxygen wherein the chimeric gene of step (a) is expressed.

Although we do use the yncM tag mentioned in this patent – however their use of YncM is as a nucleic acid fragment in the promoter region which is distinct from our purpose.

N

3. Orange Book/FDA

We also considered patents without single chain insulin to identify whether existing commercial / FDA products involved patented methods eg. storage etc., that may be broad enough to include insulin analogues like Winsulin.

Looking through the Orange Book, a drug database showing all products that have been approved - including their therapeutic equivalences, our team searched through all 101 entries that involved insulin to determine whether or not we would fall under a patent here.

Search Method

All 101 patents were collated it in an excel data table (right: screenshot of excel data sheet) and formatted with Y/N based on their expiry date. We then picked out all the patents (green) in force and ordered them by their relevant associated patents and their associated claims.

Patent Categories

1. Sequence
2. Device
3. Preparation / Storage

Interestingly, most of the patents for insulin that are still in force, surround the physical devices which are used to inject the insulin eg. automatic injection devices, or alternatively means of storage. This is unsurprising as insulin as a therapeutic has been around for over 50 years.

Click for different patent classes!

SEQUENCE

PRODUCT NAME	PRODUCT CODE	PATENTS	NATURE OF CLAIM / JUSTIFICATION OF DIFFERENCE	Y/N
INSULIN ASPART; INSULIN DEGLUDEC (RYZOGDEG 70/30)	N203313	5866538	The sequence claimed in this patent consists of Asp(B28) human insulin which we don’t have. Furthermore, it involves the actual preparation of the “insulin with glycerol and or mannitol and 5-100mM of a halogen, including chloride and specifically NaCl.” Whilst these are not relevant to us in the present stages of our projects – they have implications on how we plan to store the insulin in the future	N
INSULIN DEGLUDEC (TRESIBA)	N203314	7615532	The sequence claimed by this patent involves a 4-amino acid linker which notable involves carboxylation of at least one of the amino acids present	N
INSULIN DEGLUDEC, LIRAGLUTIDE (XULTOPHY 100/3.6)	N208583	6268343, 6458924, 7235627, 8937042	The present claim involves a GLP-1 compound with an insulin peptide. GLP-1’s are regulatory insulintoprohic compounds which are administered together with insulin in this pharmaceutical product. Importantly, the insulin used is carboxylated and with additional modifications; sequence is N_B29-(N_-(COOH(CH2)14CO)-_-Glu)desB30)	N
INSULIN DETEMIR RECOMBINANT (LEVEMINR / LEVIMER FLEXTOUCH)	N023156	5750497	Acylated insulin The sequence claimed involve acylated produts and do not reference to single chain insulin production. These acylations are additional to other modifications to the A and B chains including sequence deletions and substitutions which are not present in our sequence. This includes Gly(A21), Arg (b31), Arg(B32)-human insulin.	N
INSULIN GLARGINE; LIXISENATIDE (SOLIQUA 100/33)	N205692	9345750	Long-acting formulations of insulins The insulin formulation that is covered is specifically insulin glargine at a specific amount (300 U/mL) and not other compounds	N
INSULIN GLARGINE RECOMBINANT (APIDRA)	N021629	6221633	Novel insulin derivatives with rapid onset of action We are still squarely out of this. The primary modifications allowed by this patent are human and animal insulin substitutions. However, In Claim 2 - B30 is a -OH or the amino acid residue and furthermore, B1 is a phenylalanine residue or a hydrogen atom and B3 is a basic amino acid. These do NOT cover human insulin single chains	N

DEVICE

PRODUCT NAME	PRODUCT CODE	PATENTS	NATURE OF CLAIM / JUSTIFICATION OF DIFFERENCE	Y/N
INSULIN DEGLUDEC (TRESIBA)	N203314	6899699, 947154	Automatic injection device with reset feature	N
		8672898, 9687611	An automatic injection device with a top release mechanism	N
		8684969, 9486588	Injection device that houses torsion springs and rotatable display influencing the operative manner of dosing insulin	N
		8920383, 9132239	Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left	N
		9108002	Dial down mechanism for wind-up type pens	N
INSULIN DEGLUDEC, LIRAGLUTIDE (XULTOPHY 100/3.6)	N208583	6899699, 8672898, 8684969, 9108002, 9132239, 9457154, 9486588, 9687611	Automatic injection device with reset feature	N
INSULIN GLARGINE RECOMBINANT (LANTUS/LANTUS SOLOSTAR)	N021080	7918833	Pen-type injector with dose dial sleeve	N
INSULIN GLARGINE RECOMBINANT (LANTUS/LANTUS SOLOSTAR)	N021080	7918833	Pen-type injector with dose dial sleeve	N
INSULIN GLARGINE RECOMBINANT (TOUJEO SOLOSTAR)	N206538	7918833	Pen-type injector with dose dial sleeve	N
INSULIN GLARGINE; LIXISENATIDE (SOLIQUA 100/33)	N205692	8512297	Drive mechanisms suitable for use in drug delivery devices	N
INSULIN GLARGINE; LIXISENATIDE (SOLIQUA 100/33)	N205692	8556864, 8603044, 8679069, 8992486, 9011391, 9233211, 9408979, 9526844, 9533105, 9561331, 9604008, 9604009, 9610409, 9623189, 9775954	Pen-type injector with dose dial sleeve	N
INSULIN HUMAN (HUMULIN R, HUMULIN R PEN, HUMULUN 70/30, HUMULIN 70/30/ PEN)	N018780	7291132	Medication dispensing apparatus with triple screw threads for mechanical advantage	N
INSULIN LISPRO RECOMBINANT (HUMALOG KWIPEN)	N2057479	7291132	Medication dispensing apparatus with triple screw threads for mechanical advantage	N
INSULIN LISPRO RECOMBINANT (HUMALOG KWIPEN)	N2057479	6551992	Biosynthetic osteogenic proteins and osteogenic devices containing them both devices and the actual materials - these materials have a specific sequence and conformation to induce endochondral bone formation when disposed within a matrix. Own insulin is not synthesised to have that purpose and although it does have six cysteine residues – the patent covers a very specific sequence that is longer than our product. Furthermore this patent is only relevant to a pair of polypeptides which is unlikely our single chain, Winsulin.	N

PREPARATION / STORAGE

PRODUCT NAME	PRODUCT CODE	PATENTS	NATURE OF CLAIM / JUSTIFICATION OF DIFFERENCE	Y/N
INSULIN ASPART; INSULIN DEGLUDEC (RYZOGDEG 70/30)	N203313	5866538	The sequence claimed in this patent consists of Asp(B28) human insulin which we don’t have. Furthermore, it involves the actual preparation of the “insulin with glycerol and or mannitol and 5-100mM of a halogen, including chloride and specifically NaCl.” Whilst these are not relevant to us in the present stages of our projects – they have implications on how we plan to store the insulin in the future	N
INSULIN GLARGINE RECOMBINANT (LANTUS/LANTUS SOLOSTAR)	N021080	7476652	Acidic insulin preparations with improved stability	N
INSULIN GLARGINE RECOMBINANT (LANTUS/LANTUS SOLOSTAR)	N021080	7713930	Similar to above – this involves a storage patent where a specific human insulin construct (glargine),is preserved in polysorbate 20 and polysorbate 80; with at least one preservative and water and a specific acidic pH. Again, this is an important consideration when it comes to the long term storage of our insulin and its preparation.	N
INSULIN GLARGINE RECOMBINANT (APIDRA)	N021629	6960561, 7452860, 7696162	Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability A formulation comprising at least one insulin analog; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer, and an excipient, wherein the pharmaceutical formulation is free from or contains less than 0.4% by weight of zinc based on the insulin content of the formulation. Importantly, our insulin (at the stage of our experimental work are currently left in storage buffer	N
INSULIN LISPRO RECOMBINANT (HUMALOG KWIPEN)	N2057479	6034054	STABLE INSULIN FORMULATIONS The stable insulin formulation claimed by this patent involves claim for a stable insulin solution with a i) physiologically tolerated buffer from the group of TRIS and arginine, and a ii) monomeric insulin analogue with human insulin that has a modified B28 position and a modified B29 lysine or proline. Our sequence does not fall under these requirements in terms of modification and this patent thus would not affect us	N

@@ Line 5: / Line 5: @@
    <script src="http://code.jquery.com/jquery-2.1.0.min.js"></script>
    <link href="https://fonts.googleapis.com/css?family=Quicksand" rel="stylesheet">
 <script>
 $(document).ready(function(){
@@ Line 32: / Line 33: @@
                      $(".box").hide();
                      $(".patent_6").show();
+                }
+                if($(this).attr("value")=="10"){
+                    $(".box12").hide();
+                    $(".patent_10").show();
+                }
+                if($(this).attr("value")=="11"){
+                    $(".box12").hide();
+                    $(".patent_11").show();
+                }
+                if($(this).attr("value")=="12"){
+                    $(".box12").hide();
+                    $(".patent_12").show();
+                }
+                if($(this).attr("value")=="13"){
+                    $(".box12").hide();
+                    $(".patent_13").show();
+                }
+                if($(this).attr("value")=="14"){
+                    $(".box12").hide();
+                    $(".patent_14").show();
+                }
+                if($(this).attr("value")=="20"){
+                    $(".box10").hide();
+                    $(".patent_20").show();
+                }
+                if($(this).attr("value")=="21"){
+                    $(".box10").hide();
+                    $(".patent_21").show();
+                }
+                if($(this).attr("value")=="22"){
+                    $(".box10").hide();
+                    $(".patent_22").show();
                  }
              });
@@ Line 56: / Line 89: @@
    font-family: 'Quicksand', sans-serif;
 color: #3e3f3f;
-   font-size: 16px;
+   font-size: 20px;
    LINE-HEIGHT:20px;
@@ Line 101: / Line 134: @@
 	image-rendering: -webkit-optimize-contrast;
 	-ms-interpolation-mode: nearest-neighbor;
-  padding:0px;
-  width:90%;
-  margin-top: 0px;
-  margin-left:5%;,
-  margin-right:5%;
-background: #fff;
 }
@@ Line 147: / Line 174: @@
    box-sizing: border-box;
    background-clip: padding-box;
-  padding:0 20px 20px 20px;
    height:750px;
    width:100%;
@@ Line 166: / Line 192: @@
 }
-  .box{
+  .box, .box12, .box10 {
          padding: 20px;
          display: none;
@@ Line 209: / Line 235: @@
    padding:0 10px 10px 10px;
    max-height:2px;
-   min-width:800px;
+   margin-left:10%
+  width:80%
 }
@@ Line 230: / Line 257: @@
    background:#93bcc1;
    border-color: #93bcc1;
+}
+.box7 {
+  background:#93bcc1;
+  border:0px solid;
+  border-color: #93bcc1;
+  margin-top: 10px;
+  box-sizing: border-box;
+  background-clip: padding-box;
+  padding:0 10px 10px 10px;
+  max-height:2px;
+  max-width:400px;
 }
@@ Line 237: / Line 276: @@
 <div class="container-fluid">
-<div class = "bannerbox" style ="background-color:#e2e2e2">
+<div class = "row" style ="background-color:#e2e2e2;margin-top:60px">
-<div class = "center">
+    <img class = "img-responsive" style="margin-left:10%" src="https://static.igem.org/mediawiki/2017/a/af/T--Sydney_Australia--LawBanner.gif" width="80%">
-    <img src="https://static.igem.org/mediawiki/2017/a/af/T--Sydney_Australia--LawBanner.gif" width="100%">
-</div>
-</div>
 </div>
@@ Line 250: / Line 286: @@
 <div class="box1">
 </div>
-<center><h4>In constructing the sequence of a single chain insulin we had to ensure that our sequence was not under any existing patents so that we could submit our sequence into the Open Source iGEM registry. With a bit of help from <a href="https://2017.igem.org/Team:Sydney_Australia/HP/Gold_Integrated">Maxwell Lawyers</a> we went through several <u>single chain</u> insulin patents, <u>method</u> patents and existing patents for current insulin dispensing <u>devices/therapeutics</u> using the FDA orange book. The goal was to make sure our work did <i>not</i> come under any existing patents so we would not infringe any ownership rights.<br><br></h4><center>
+<center><h4><br>In constructing the sequence of a single chain insulin we had to ensure that our sequence was not under any existing patents so that we could submit our sequence into the Open Source iGEM registry. With a bit of help from <a href="http://www.maxpat.com/about-us-2/our-team/leonard-mancini/">Maxwell Lawyers</a> we went through several <u>single chain</u> insulin patents, <u>method</u> patents and existing patents for current insulin dispensing <u>devices/therapeutics</u> using the FDA orange book. The goal was to make sure our work did <i>not</i> come under any existing patents so we would not infringe any ownership rights.<br><br> Importantly, we recognise the difficulty of being thorough with all existing patents and the content provided is not intended to be legal advice and should not be used as such. To determine whether you are infringing a patent; the best course of action is to seek a qualified patent lawyer. <br><br>To examine the way we approached patents - please <i>click on the links below</i> for easy navigation to each section.</h4></center>
 </div>
 </div>
+<div class="row" style="height:5vw;"></div>
 <div class = "row">
@@ Line 263: / Line 300: @@
 </div>
 <div class = "col-xs-4">
+<div align = "center">
       <a href="#nav2"><center><img src="https://static.igem.org/mediawiki/2017/7/77/T--Sydney_Australia--patent-methodpatent.png" height="200px"></center></a>
+</div>
 </div>
 <div class = "col-xs-4">
@@ Line 273: / Line 312: @@
 </div>
+<div class="row" style="height:5vw;"></div>
 <div class = "row">
@@ Line 279: / Line 319: @@
 <div class="box3">
 </div>
-<center><br><br><h4>After our chat with Uppsala (check it out in <a href="https://2017.igem.org/Team:Sydney_Australia/Collaborations">collaborations</a>), our team realised that patents are a very poorly understood area, particularly for young aspiring scientists with new and challenging ideas. <br><br>With a resident legal student in our team - we created a quick checklist on <i>How to read a patent</i><br></h4></center>
+<center><br><h4>After our chat with Uppsala (check it out in <a href="https://2017.igem.org/Team:Sydney_Australia/Collaborations">collaborations</a>), our team realised that patents are a very poorly understood area, particularly for young aspiring scientists with new and challenging ideas. <br><br>With a resident legal student in our team - we created a quick checklist on <i>How to read a patent</i><br></h4></center>
 <h2><center>KEY CONSIDERATIONS</center></h2>
 <h4><center><b>1.</b>  Patents give an exclusive commercial right to the invention aka. a monopoly
@@ Line 290: / Line 330: @@
 <div class="content">
 <div align=center>
-<img src="https://static.igem.org/mediawiki/2017/7/76/T--Sydney_Australia--patent-checklist.png" width="80%">
+<img src="https://static.igem.org/mediawiki/2017/7/76/T--Sydney_Australia--patent-checklist.png" width="100%">
 </div>
 </div>
 </div>
 <div class = "row">
@@ Line 300: / Line 339: @@
 <div class = "col-xs-1"></div>
 <div class= "col-xs-10">
-	<h3><center> It is with this little checklist that we approached the analysis of a wide range of patents:</center></h3></div>
+<h3>And it is with this checklist that we approached the analysis of a wide range of patents below.</center></h3>
+</div>
 <div class ="col-xs-1"></div>
 </div>
@@ Line 313: / Line 353: @@
 <div class = "row">
 <div class = "content" id="please">
-<center><h1><b>1.</b> Single Chain Insulin Patents</h1><center>
+	<center><h1><b>1.</b> Single Chain Insulin Patents</h1></center>
-<div class="box2"></div>
+<div class="box2">
-<center><h4>Although our team attempted to be thorough, we recognise that not all patents can be checked. However, we targeted patents with the greatest relevance to avoid legal suits that may arise. Our primary concern was <u>single chain</u> insulin patents since they have only been recently explored in greater depth and quoted to have benefits like enhanced thermostability. As these single chain insulins are likely to be the next insulin product in the market, we wanted to create one, outside the scope of existing patents, to characterise and compare our product.
+</div>
-<br><br> Importantly there is an exception in patents for research purposes. This means that if the work you performed is for research purposes only, you do not infringe the relevant patent. You can<u>not</u> however, submit the part into the open source registry or try and commercialise it. As we are submitting 'Winsulin,' our single chain insulin, it must not be patented.<br><br>
+	<center><h4><br>Although our team attempted to be thorough, we recognise that not all patents can be checked. However, we targeted patents with the greatest relevance to avoid legal suits that may arise. Our primary concern was <u>single chain</u> insulin patents since they have only been recently explored in greater depth and quoted to have benefits like enhanced thermostability. As these single chain insulins are likely to be the next insulin product in the market, we wanted to create one, outside the scope of existing patents, to characterise and compare our product.
-</center>
+<br><br> Importantly there is an exception in patents for research purposes. This means that if the work you performed is for research purposes only, you do not infringe the relevant patent. You can<u>not</u> however, submit the part into the open source registry or try and commercialise it. As we are submitting 'Winsulin,' our single chain insulin, it must not be patented.<br><br></center>
 </div>
 </div>
 <div class = "row">
@@ Line 356: / Line 395: @@
 <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+<div style="overflow-x:auto;">
 <table class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext 0.5pt;
   mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt">
@@ Line 423: / Line 463: @@
    mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
    color:black">Both insulin A and B chains involve R groups which stand for
-   modifications <span class="SpellE">eg</span>. carboxylation. As our <span class="GramE">insulin</span> B chain does not contain any modifications (except
+   modifications <span class="SpellE">eg</span>. carboxylation. As our <span class="GramE">insulin</span> B chain does not contain any modifications (except for a substituted glycine on the A chain), our construct is outside the patent<o:p></o:p></span></p>
-  an additional glycine at the A chain), our construct is outside the patent<o:p></o:p></span></p>
    <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
    mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
@@ Line 511: / Line 550: @@
    font-family:Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
    Helvetica;color:black">–</span><span lang="EN-AU" style="font-size:14.0pt;
-   font-family:Quicksand;mso-bidi-font-family:Times;color:black"> QR . . . RR </span><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
+   font-family:Quicksand;mso-bidi-font-family:Times;color:black"> QR . . . KR </span><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
    Helvetica;mso-bidi-font-family:Helvetica;color:black">–</span><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:
    Times;color:black"> A-chain</span><span lang="EN-AU" style="font-size:14.0pt;
@@ Line 612: / Line 651: @@
    </td>
   </tr>
-</tbody></table>
+</tbody></table></div>
 </div>
 	<div class="patent_2 box">
 	<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
@@ Line 633: / Line 671: @@
 <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+<div style="overflow-x:auto;">
 <table class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
   mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt">
@@ Line 717: / Line 756: @@
    <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Our B and A chain are human
-   insulin chains although our A chain includes a modification (additional
+   insulin chains although our A chain includes a modification (A21 substitution into
    glycine)<o:p></o:p></span></p>
    <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
@@ Line 768: / Line 807: @@
    </td>
   </tr>
-</tbody></table></div>
+</tbody></table></div></div>
      <div class="patent_3 box">
 <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
@@ Line 785: / Line 824: @@
 <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+<div style="overflow-x:auto;">
 <table class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
   mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt">
@@ Line 986: / Line 1,025: @@
    </td>
   </tr>
-</tbody></table></div>
+</tbody></table></div></div>
      <div class="patent_4 box">
      <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
@@ Line 1,002: / Line 1,041: @@
 <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+<div style="overflow-x:auto;">
 <table class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
   mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt">
@@ Line 1,125: / Line 1,164: @@
    mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt">
    <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">In our sequence construct </span><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
-   Helvetica;mso-bidi-font-family:Helvetica">–</span><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"> the A chain is 22 amino acids
+   Helvetica;mso-bidi-font-family:Helvetica">–</span><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"> the A chain is 21 amino acid however it is a modification of the natural protein. It does not fall within an 'analogue' as there is no complete addition/deletion of an amino acid.<b style="mso-bidi-font-weight:normal"><o:p></o:p></b></span></p>
-  long. Just like in the B-chain (it only covers a TOTAL of 21 AA). Even though
-  our A chain contains the addition of an amino acid (glycine), the length is
-  too long for the patent to operate over.<b style="mso-bidi-font-weight:normal"><o:p></o:p></b></span></p>
    </td>
    <td width="6%" style="width:6.16%;border-top:none;border-left:none;
@@ Line 1,297: / Line 1,333: @@
    </td>
   </tr>
-</tbody></table>
+</tbody></table></div>
 </div>
      <div class="patent_5 box">
@@ Line 1,315: / Line 1,351: @@
 <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+<div style="overflow-x:auto;">
 <table class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
   mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt">
@@ Line 1,364: / Line 1,400: @@
    the entire C-peptide to 12 amino acids and has the general formula of B-X-A
    where our linker is<o:p></o:p></span></p>
-   <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">QRGGGSGGGQRR<o:p></o:p></span></p>
+   <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">QRGGGSGGGQKR<o:p></o:p></span></p>
    <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
    </td>
@@ Line 1,600: / Line 1,636: @@
    mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt">
    <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Our A-chain does not contain
-   the relevant substitution and only an additional glycine<o:p></o:p></span></p>
+   the relevant substitution<o:p></o:p></span></p>
    </td>
    <td width="6%" style="width:6.18%;border-top:none;border-left:none;
@@ Line 1,610: / Line 1,646: @@
    </td>
   </tr>
-</tbody></table> </div>
+</tbody></table> </div></div>
      <div class="patent_6 box">
      <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
 <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:
 normal"><span lang="EN-AU" style="font-size:20.0pt;font-family:Quicksand">STOWELL
@@ Line 1,631: / Line 1,666: @@
 <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+<div style="overflow-x:auto;">
 <table class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
   mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt">
@@ Line 1,709: / Line 1,744: @@
    mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt">
    <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Only the A chain is modified<o:p>&nbsp;</o:p></span></p>
    </td>
    <td width="6%" style="width:6.54%;border-top:none;border-left:none;
    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
    mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
-   mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
+   mso-border-alt:solid windowtext .5pt;background:#FFC8CD;mso-background-themecolor:
    accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt">
-   <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Y<o:p></o:p></span></p>
+   <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N<o:p></o:p></span></p>
    </td>
   </tr>
@@ Line 1,782: / Line 1,818: @@
    </td>
   </tr>
-</tbody></table> </div>
+</tbody></table></div></div>
-</div>
-<div class="row" style="height:10vw;">
-</div>
 </div>
+<div class="row" style="height:10vh;"></div>
 </div>
@@ Line 1,797: / Line 1,831: @@
 <div class = "row">
 <div class = "content" id="please">
-<center><h1><b>2.</b> Method Patents</h1></center>
+	<center><h1><b>2.</b> Method Patents</h1></center>
 <div class="box4"></div>
-<h4><center><br>In looking at patents, we first considered looking at different methods of production – particularly whether or not bacillus secretory methods are patented for insulin production. <br><br>From a preliminary search, bacillus secretion has been previously patented however most are now expired. If it is possible to find a patent using the same method of production as a previously patented product, it will not infringe anyone elses intellectual property. </h4>
+	<br><h4><center>In looking at patents, we first considered looking at different methods of production – particularly whether or not Bacillus secretory methods are patented for insulin production. <br><br>From a preliminary search, Bacillus secretion has been previously patented however most are now expired. If it is possible to find a patent using the same method of production as a previously patented product, it will not infringe anyone elses intellectual property.<br><br></h4></center>
 </div>
+</div>
+<div class="row">
+       <center><select>
+            <option value="choose">Choose a patent</option>
+            <option value="10">Stahl et al. 1985</option>
+            <option value="11">Kovacevic et al. 1991</option>
+            <option value="12">Berka et al. 1996</option>
+            <option value="13">Widner et al. 2001</option>
+            <option value="14">Bedzyk et al. 2001</option>
+        </center></select></center>
+    </div>
+    <div class="row">
+    <div class="content" id ="please">
+    <div class="choose box12">
+    	<h4> relatively important PATENT STUFF</h4>
+    </div>
+    <div class="patent_10 box12">
+   		<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:20.0pt;font-family:Quicksand">STAHL ET AL.<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:16.0pt;font-family:Quicksand">Method for Producing
+Heterologous Proteins<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:16.0pt;font-family:Quicksand">Patent No: US4801536A<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:16.0pt;font-family:Quicksand">November 10th, 1985</span><span style="font-size:14.0pt;font-family:Quicksand"><br style="mso-special-character:
+line-break">
+<!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
+<!--[endif]--><o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:20.0pt;font-family:Quicksand">STAHL ET AL.<o:p></o:p></span></p>
+<div style="overflow-x:auto;">
+<table class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
+ mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt">
+ <tbody><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:15.55pt">
+  <td width="49%" style="width:49.86%;border:solid windowtext 1.0pt;mso-border-alt:
+  solid windowtext .5pt;background:#FAD990;padding:0cm 5.4pt 0cm 5.4pt;
+  height:15.55pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand">CLAIMS<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="44%" style="width:44.72%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#FAD990;padding:0cm 5.4pt 0cm 5.4pt;height:15.55pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand">COMPARISON WITH OUR METHOD<o:p></o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.42%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#FAD990;padding:0cm 5.4pt 0cm 5.4pt;height:15.55pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand">Y/N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:1;height:33.0pt">
+  <td width="94%" colspan="2" style="width:94.58%;border:solid windowtext 1.0pt;
+  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:33.0pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Status: EXPIRED. Now this
+  patent has expired. Importantly </span><span style="font-size:14.0pt;
+  font-family:Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
+  Helvetica">–</span><span style="font-size:14.0pt;font-family:Quicksand"> it
+  covers our <br>
+  project as we have a heterologous protein being attached via a secretion tag
+  to the actual plasmid vector design.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.42%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
+  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:33.0pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Y<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:2">
+  <td width="49%" style="width:49.86%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">A method for producing a
+  heterologous protein in a bacterial host cell such that the protein is
+  exported from the host cell into the culture medium, the method comprising
+  culturing in a bacterial culture medium a genetically engineered bacterial
+  strain containing a fusion DNA sequence which comprises a first nucleotide
+  sequence encoding at least an N-terminal portion of a <span class="SpellE">flagellin</span>
+  protein native to the bacterial host cell species and a second nucleotide
+  sequence encoding the heterologous protein, said first nucleotide sequence
+  being linked via its 3' terminus to the 5' terminus of the second DNA
+  sequence and said fusion DNA sequence being operatively linked to an
+  expression control sequence and wherein said N-terminal portion results in
+  the export of said heterologous protein.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="44%" style="width:44.72%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Our plasmid falls directly
+  into this means of production. As this patent has since expired and we fall
+  under it </span><span style="font-size:14.0pt;font-family:Quicksand;
+  mso-fareast-font-family:Helvetica;mso-bidi-font-family:Helvetica">– the
+  methods that are encoded are free to be used and thus not for law suit.</span><span style="font-size:14.0pt;font-family:Quicksand"><o:p></o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.42%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
+  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Y<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:3">
+  <td width="49%" style="width:49.86%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">A plasmid as identified in any
+  of Tables 2 to 5 of the specification by the designation <span class="SpellE">pSPA</span>
+  or <span class="SpellE">pSPB</span>.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="44%" style="width:44.72%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">WB800 plasmid<o:p></o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.42%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:4;mso-yfti-lastrow:yes;height:60.3pt">
+  <td width="49%" style="width:49.86%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:60.3pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">A DNA sequence flanked by and
+  in proper reading frame with a non-wild type open reading frame encoding a
+  secretory signal sequence having the amino acid sequence: pSPB4, pSPB9,
+  pSPB19, pSPB20, pSPB23, pSPB28<o:p></o:p></span></p>
+  </td>
+  <td width="44%" style="width:44.72%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:60.3pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">None of the plasmids mentioned
+  are being used nor are the AA sequences that are described in greater detail
+  in the patent<o:p></o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.42%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:60.3pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+</tbody></table></div>
+	</div>
+    <div class="patent_11 box12">
+		<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:20.0pt;font-family:Quicksand">KOVACEVIC ET AL.<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:16.0pt;font-family:Quicksand">Method for expression and
+secretion in Bacillus<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:16.0pt;font-family:Quicksand">Patent No: US5032510A<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:16.0pt;font-family:Quicksand">July 16th, 1991<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+<div style="overflow-x:auto;">
+<table class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
+ mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt">
+ <tbody><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:30.25pt">
+  <td width="48%" style="width:48.22%;border:solid windowtext 1.0pt;mso-border-alt:
+  solid windowtext .5pt;background:#93BCC1;padding:0cm 5.4pt 0cm 5.4pt;
+  height:30.25pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand">CLAIMS<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="46%" style="width:46.22%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#93BCC1;padding:0cm 5.4pt 0cm 5.4pt;height:30.25pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand">COMPARISON WITH OUR METHOD<o:p></o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.56%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#93BCC1;padding:0cm 5.4pt 0cm 5.4pt;height:30.25pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand">Y/N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:1;height:30.25pt">
+  <td width="94%" colspan="2" style="width:94.44%;border:solid windowtext 1.0pt;
+  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:30.25pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">STATUS: Expired. The invention
+  method claimed is now open source.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.56%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
+  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:30.25pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Y<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:2;height:30.25pt">
+  <td width="48%" style="width:48.22%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:30.25pt">
+  <p class="MsoNormal"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">1. A method for expressing a
+  peptide in Bacillus, said method comprising&nbsp;<br style="mso-special-character:
+  line-break">
+  <!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
+  <!--[endif]--><o:p></o:p></span></p>
+  </td>
+  <td width="46%" style="width:46.22%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:30.25pt">
+  <p class="MsoNormal"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">We are expressing a
+  peptide/polypeptide in Bacillus<o:p></o:p></span></p>
+  <p class="MsoNormal"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.56%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
+  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:30.25pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Y<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:3">
+  <td width="48%" style="width:48.22%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">a) transforming a Bacillus
+  host cell which is rendered competent for transformation with a recombinant
+  DNA expression vector which is selectable and capable of replication in said
+  host cell, said vector comprising&nbsp;<br style="mso-special-character:line-break">
+  <!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
+  <!--[endif]--><o:p></o:p></span></p>
+  </td>
+  <td width="46%" style="width:46.22%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Our Bacillus host cell was
+  made competent specifically for recombinant DNA uptake. The expression vector
+  is also capable of replication<o:p></o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.56%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
+  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Y<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:4">
+  <td width="48%" style="width:48.22%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">1) the transcriptional and
+  translational activating sequence of the Staphylococcus aureus nuclease gene
+  and<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">2) a cloned DNA sequence that
+  codes for a polypeptide, and<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="46%" style="width:46.22%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">This vector however does not
+  include a Staph. Aureus nuclease gene.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span class="SpellE"><span style="font-size:14.0pt;font-family:Quicksand">Winsulin</span></span><span style="font-size:14.0pt;font-family:Quicksand"> is a single poly-peptide
+  chain, while Insulin is a dual-peptide complex<o:p></o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.56%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:5;mso-yfti-lastrow:yes;height:146.25pt">
+  <td width="48%" style="width:48.22%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:146.25pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">b) culturing said transformed
+  cell under conditions suitable for expression of said polypeptide, subject to
+  the limitation 1) that said cloned DNA sequence that codes for said
+  polypeptide and said transcriptional and translational activating sequence
+  are immediately adjacent, in translational reading frame and positioned for
+  expression of said polypeptide and 2) that said cloned DNA sequence that
+  codes for said polypeptide is exclusive of the nucleotide triplet that codes
+  for the N-terminal amino acid of said polypeptide when said amino acid is
+  methionine.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="46%" style="width:46.22%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:146.25pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">This potentially could be an
+  issue, depending on the reading and interpretation. However, since we fall
+  outside of the above key aspects of this individual claim, we are still in
+  the clear.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.56%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:146.25pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+</tbody></table></div>
+    </div>
+    <div class="patent_12 box12">
+    	<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:20.0pt;font-family:Quicksand">BERKA ET AL.<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:16.0pt;font-family:Quicksand">Heterologous polypeptide
+expressed in filamentous fungi, processes for their preparation, and vectors
+for their preparation<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:16.0pt;font-family:Quicksand">Patent No: EP0369817B1<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:16.0pt;font-family:Quicksand">April 24th, 1996<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+<div style="overflow-x:auto;">
+<table class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
+ mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt">
+ <tbody><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:14.85pt">
+  <td width="48%" style="width:48.22%;border:solid windowtext 1.0pt;mso-border-alt:
+  solid windowtext .5pt;background:#E8939C;padding:0cm 5.4pt 0cm 5.4pt;
+  height:14.85pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand">CLAIMS<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="46%" style="width:46.22%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#E8939C;padding:0cm 5.4pt 0cm 5.4pt;height:14.85pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand">COMPARISON WITH OUR METHOD<o:p></o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.56%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#E8939C;padding:0cm 5.4pt 0cm 5.4pt;height:14.85pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand">Y/N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:1;height:86.85pt">
+  <td width="94%" colspan="2" style="width:94.44%;border:solid windowtext 1.0pt;
+  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:86.85pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Status: EXPIRED<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">The expiry date of this patent
+  is extremely critical as it patents the production of proteins in a Bacillus
+  cell with multiple gene knockouts. Importantly, the strain used by us, WB800
+  contains 8 protease knockouts and thus falls within the scope of this patent.
+  As the patent has expired </span><span style="font-size:14.0pt;font-family:
+  Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:Helvetica">–this
+  means of production is available for use.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.56%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
+  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:86.85pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Y<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:2;height:197.25pt">
+  <td width="48%" style="width:48.22%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:197.25pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Claim 1<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">A&nbsp;Bacillus&nbsp;cell
+  characterised in containing a mutation in the&nbsp;<span class="SpellE">epr</span>&nbsp;gene,
+  said&nbsp;<span class="SpellE">epr</span>&nbsp;gene encoding a protein
+  comprising the amino acid sequence of Figure 6 or an evolutionary homologue
+  thereof of other&nbsp;Bacillus&nbsp;species, having protease activity, said
+  mutation resulting in inhibition of the production by said cell of <span class="SpellE">proteolytically</span> active&nbsp;<span class="SpellE">epr</span>&nbsp;gene
+  product.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="46%" style="width:46.22%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:197.25pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">We have a mutation in the <span class="SpellE">epr</span> gene in WB800, which renders the EPR protein inactive
+  such that it does not have a <span class="SpellE">proteolytically</span> active
+  <span class="SpellE">epr</span> gene product<o:p></o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.56%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
+  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:197.25pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Y<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:3;mso-yfti-lastrow:yes">
+  <td width="48%" style="width:48.22%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Claim 16<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">A method for producing a
+  heterologous polypeptide in a&nbsp;Bacillus&nbsp;cell, characterised in
+  comprising: introducing into said cell a gene encoding said heterologous
+  polypeptide, modified to be expressed in said cell,
+  said&nbsp;Bacillus&nbsp;cell containing mutations in the&nbsp;<span class="SpellE">apr</span>&nbsp;and&nbsp;<span class="SpellE">npr</span>&nbsp;genes,
+  and further containing mutations in one or more of the genes encoding the <span class="SpellE">Epr</span> protease, RP-I, or RP-II, said <span class="SpellE">Epr</span>,
+  RP-I and RP-II comprising the amino acid sequences set out in Figures 6, 10
+  and 14 respectively, or evolutionary homologues thereof of
+  other&nbsp;Bacillus&nbsp;species, having protease activity, wherein said
+  mutation results in the inhibition of the production by said cell of <span class="SpellE">proteolytically</span> active <span class="SpellE">Epr</span>
+  protease, RP-I or RP-II.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="46%" style="width:46.22%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">We have a mutation in <span class="SpellE">aprE</span> and <span class="SpellE">nprE</span> <span class="GramE">and also</span> <span class="SpellE">epr</span> and thus fall
+  within this claim.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.56%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
+  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Y<o:p></o:p></span></p>
+  </td>
+ </tr>
+</tbody></table></div>
+	</div>
+    <div class="patent_13 box12">
+    	<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:20.0pt;font-family:Quicksand">WIDNER ET AL.<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:16.0pt;font-family:Quicksand">Methods for producing a
+polypeptide in a Bacillus cell<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:16.0pt;font-family:Quicksand">Patent No: US6255076B1<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:16.0pt;font-family:Quicksand">July 3rd, 2001<o:p></o:p></span></p>
+<div style="overflow-x:auto;">
+<table class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
+ mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt">
+ <tbody><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes">
+  <td width="47%" style="width:47.72%;border:solid windowtext 1.0pt;mso-border-alt:
+  solid windowtext .5pt;background:#9EA6EA;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand">CLAIMS<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="46%" style="width:46.84%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#9EA6EA;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand">COMPARISON WITH OUR METHOD<o:p></o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.44%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#9EA6EA;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand">Y/N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:1">
+  <td width="47%" style="width:47.72%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoListParagraphCxSpFirst" align="center" style="text-align:center;
+  text-indent:-18.0pt;mso-list:l0 level1 lfo1"><!--[if !supportLists]--><span style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Quicksand;
+  mso-bidi-font-family:Quicksand"><span style="mso-list:Ignore">1.<span style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style="font-size:14.0pt;font-family:Quicksand">A method for producing a
+  polypeptide, comprising:<o:p></o:p></span></p>
+  <p class="MsoListParagraphCxSpLast" align="center" style="text-align:center;
+  text-indent:-18.0pt;mso-list:l0 level1 lfo1"><!--[if !supportLists]--><span style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Quicksand;
+  mso-bidi-font-family:Quicksand"><span style="mso-list:Ignore">2.<span style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">(a) cultivating
+  a&nbsp;Bacillus&nbsp;cell in a medium conducive for the production of the
+  polypeptide, wherein the&nbsp;Bacillus&nbsp;cell comprises a nucleic acid
+  construct comprising a tandem promoter in which each promoter sequence of the
+  tandem promoter is operably linked to a nucleic acid sequence encoding the
+  polypeptide, wherein the tandem promoter comprises promoters selected from
+  the group consisting of the <span class="SpellE">amyL</span> promoter, <span class="SpellE">amyQ</span> promoter, <span class="SpellE">aprH</span> promoter, <span class="SpellE">cryIIIA</span> promoter, <span class="SpellE">subtilisin</span>
+  Carlsberg gene promoter, and consensus promoters of the <span class="SpellE">amyL</span>
+  promoter, <span class="SpellE">amyQ</span> promoter, <span class="SpellE">aprH</span>
+  promoter, <span class="SpellE">cryIIIA</span> promoter, and <span class="SpellE">subtilisin</span>
+  Carlsberg gene promoter having the sequence TTGACA for the </span><span style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
+  mso-bidi-font-family:Helvetica">“</span><span style="font-size:14.0pt;
+  font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
+  Calibri">_</span><span style="font-size:14.0pt;font-family:Quicksand;
+  mso-fareast-font-family:Helvetica;mso-bidi-font-family:Helvetica">35” region
+  and TATAAT for the “</span><span style="font-size:14.0pt;font-family:Calibri;
+  mso-fareast-font-family:Calibri;mso-bidi-font-family:Calibri">_</span><span style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
+  mso-bidi-font-family:Helvetica">10” region; and</span><span style="font-size:
+.0pt;font-family:Quicksand"><o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">(b) isolating the polypeptide
+  from the cultivation medium.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="46%" style="width:46.84%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">We do not have a tandem
+  promoter <span class="GramE">series,</span> therefore we fall outside of this
+  claim.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">We are also using the </span><span style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
+  mso-bidi-font-family:Helvetica">… promoter, which is not listed there.</span><span style="font-size:14.0pt;font-family:Quicksand"><o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">We will be cultivating the
+  medium for polypeptide isolation however.<o:p></o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.44%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:2;mso-yfti-lastrow:yes;height:112.05pt">
+  <td width="47%" style="width:47.72%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:112.05pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">11. A method for producing a
+  polypeptide, comprising:<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">(a) cultivating
+  a&nbsp;Bacillus&nbsp;cell in a medium conducive <span class="GramE">for the
+  production of</span> the polypeptide, wherein the&nbsp;Bacillus&nbsp;cell
+  comprises a nucleic acid construct comprising<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">(<span class="SpellE">i</span>)
+  a consensus promoter obtained from&nbsp;Bacillus&nbsp;<span class="SpellE">amyloliquefaciens</span>&nbsp;alpha-amylase
+  gene (<span class="SpellE">amy</span> Q)
+  or&nbsp;Bacillus&nbsp;subtilis&nbsp;alpha-amylase gene (<span class="SpellE">amy</span>
+  E) having the sequence TTGACA for the </span><span style="font-size:14.0pt;
+  font-family:Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
+  Helvetica">“</span><span style="font-size:14.0pt;font-family:Calibri;
+  mso-fareast-font-family:Calibri;mso-bidi-font-family:Calibri">_</span><span style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
+  mso-bidi-font-family:Helvetica">35” region and TATAAT for the “</span><span style="font-size:14.0pt;font-family:Calibri;mso-fareast-font-family:Calibri;
+  mso-bidi-font-family:Calibri">_</span><span style="font-size:14.0pt;
+  font-family:Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
+  Helvetica">10” region operably linked to a single copy of a nucleic acid
+  sequence encoding the polypeptide and</span><span style="font-size:14.0pt;
+  font-family:Quicksand"><o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">(ii) an mRNA
+  processing/stabilizing sequence located downstream of the consensus promoter
+  and upstream of the nucleic acid sequence encoding the polypeptide; and<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">(b) isolating the polypeptide
+  from the cultivation medium.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="46%" style="width:46.84%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:112.05pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Arguable </span><span style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
+  mso-bidi-font-family:Helvetica">– how to define whether</span><span style="font-size:14.0pt;font-family:Quicksand"> the medium we will use will
+  be </span><span style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
+  Helvetica;mso-bidi-font-family:Helvetica">‘conductive’ or not is vague.</span><span style="font-size:14.0pt;font-family:Quicksand"><o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">We are not using a consensus
+  promoter from Bacillus <span class="SpellE">amyloliquefaciens</span>, but are
+  using the Bacillus subtilis strain. The promoter we have selected is p-<span class="SpellE">Spac</span><o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">We also do not have an mRNA
+  processing or stabilising sequence in our <span class="SpellE">gblock</span>.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">We are isolating our
+  polypeptide from the cultivation medium.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.44%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:112.05pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+</tbody></table></div>
+    </div>
+    <div class="patent_14 box12">
+    <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+    <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:20.0pt;font-family:Quicksand">BEDZYK ET AL.<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:16.0pt;font-family:Quicksand">Natural promoters for gene
+expression and metabolic monitoring in Bacillus species<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:16.0pt;font-family:Quicksand">Patent No: EP1294909 A2<o:p></o:p></span></p>
+<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:16.0pt;font-family:Quicksand">June 29th, 2001<o:p></o:p></span></p>
+<div style="overflow-x:auto;">
+<table class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
+ mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt">
+ <tbody><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:7.95pt">
+  <td width="48%" style="width:48.22%;border:solid windowtext 1.0pt;mso-border-alt:
+  solid windowtext .5pt;background:#FAD990;padding:0cm 5.4pt 0cm 5.4pt;
+  height:7.95pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand">CLAIMS<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="46%" style="width:46.34%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#FAD990;padding:0cm 5.4pt 0cm 5.4pt;height:7.95pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand">COMPARISON WITH OUR METHOD<o:p></o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.44%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#FAD990;padding:0cm 5.4pt 0cm 5.4pt;height:7.95pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:15.0pt;font-family:Quicksand">Y/N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:1;height:21.9pt">
+  <td width="94%" colspan="2" style="width:94.56%;border:solid windowtext 1.0pt;
+  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:21.9pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><u><span style="font-size:14.0pt;font-family:Quicksand"><o:p><span style="text-decoration:
+   none">&nbsp;</span></o:p></span></u></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><u><span style="font-size:14.0pt;font-family:Quicksand">Legal Status</span></u><span style="font-size:14.0pt;font-family:Quicksand">: abandoned patent<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Once a patent is abandoned it
+  does not have any effect.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.44%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:21.9pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:2;mso-yfti-lastrow:yes;height:47.05pt">
+  <td width="48%" style="width:48.22%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:47.05pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">A method for the expression of
+  a coding region of interest in a Bacillus <span class="SpellE">sp</span>
+  comprising:<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">a) providing a transformed
+  Bacillus <span class="SpellE">sp</span> cell having a chimeric gene comprising
+  a nucleic acid fragment comprising the promoter region of a Bacillus gene
+  operably linked to a coding region of interest expressible in a Bacillus <span class="SpellE">sp</span>, wherein the nucleic acid fragment comprising the
+  promoter region of a Bacillus gene is selected from the group consisting of <span class="SpellE">narGHJT</span>, <span class="SpellE">csn</span>,&nbsp;<span class="SpellE">yncM</span>, <span class="SpellE">yvyD</span>, <span class="SpellE">yvaWXY</span>,
+  <span class="SpellE">ydjL</span>, <span class="SpellE">sunA</span>, and <span class="SpellE">yolIJK</span> and homologues thereof; and<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">b) growing the transformed
+  Bacillus <span class="SpellE">sp</span> cell of step (a) in the absence of
+  oxygen wherein the chimeric gene of step (a) is expressed.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="46%" style="width:46.34%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:47.05pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">Although we do use the <span class="SpellE">yncM</span> tag mentioned in this patent </span><span style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
+  mso-bidi-font-family:Helvetica">– however their use of <span class="SpellE">YncM</span>
+  is as a nucleic acid fragment in the promoter region which is distinct from
+  our purpose.</span><span style="font-size:14.0pt;font-family:Quicksand"><o:p></o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.44%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:47.05pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:Quicksand">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+</tbody></table></div>
+	</div>
+</div>
+<div class="row" style="height:10vh;"></div>
 </div>
 <div class = "row" id = "nav3">
 <div class = "content" id="please">
-<div class = "insert'></div>
+<div class = "insert"></div>
 </div>
 </div>
@@ Line 1,811: / Line 2,583: @@
 <div class = "row">
 <div class = "content" id="please">
-<center><h1><b>3.</b> Orange Book / FDA</h1></center>
+	<center><h1><b>3.</b> Orange Book/FDA</h1></center>
 <div class="box5"></div>
-<h4><center><br>We also, for thoroughness, considered patents without single chain insulin to identify whether existing commercial / FDA products involved patented methods, that may be broad enough to include both insulin and single chain insulin. <br><br>Looking through the Orange Book, a drug database showing all products that have been approved -  including their therapeutic equivalences, our team searched through ALL 101 ENTRIES that corresponded to insulin to determine whether or not we fell within a claim. </h4>
+	<h4><center><br>We also considered patents without single chain insulin to identify whether existing commercial / FDA products involved patented methods eg. storage etc., that may be broad enough to include insulin analogues like Winsulin. <br><br>Looking through the Orange Book, a drug database showing all products that have been approved -  including their therapeutic equivalences, our team searched through all 101 entries that involved insulin to determine whether or not we would fall under a patent here.<br></h4></div>
+</div>
+<div class = "row" id = "nav3">
+<div class = "content" id="please">
+<center><h1>Search Method</h1></center>
+<center><div class="box7"></div></center>
+<div class="row">
+<div align="center">
+<img src="https://static.igem.org/mediawiki/2017/4/45/T--Sydney_Australia--patent-orangebookfda.png" width="90%">
 </div>
 </div>
+<div class ="row">
+<div class = "col-xs-6">
+<div align = "center">
+<h4><br><br>All 101 patents were collated it in an excel data table (right: <u>screenshot of excel data sheet</u>) and formatted with Y/N based on their expiry date. We then picked out all the patents (<i>green</i>) in force and ordered them by their relevant associated patents and their associated claims.
+<br></h4>
+<h3>Patent Categories</h3>
+<h4>1.	Sequence
+<br>2.	Device
+<br>3.	Preparation / Storage
+<br><br>Interestingly, most of the patents for insulin that are still in force, surround the physical devices which are used to inject the insulin eg. automatic injection devices, or alternatively means of storage. This is unsurprising as insulin as a therapeutic has been around for over 50 years.
+<br></h4>
+</div>
+</div>
+<div class = "col-xs-6">
+  <br><br><br>
+	<img src="https://static.igem.org/mediawiki/2017/9/94/T--Sydney_Australia--patent-excelspreadsheet.png" width = "100%">
+</div>
+</div>
+<div class="row" style="height:5vw;"></div>
+<div class="row">
+       <center><select>
+            <option value="choose">Choose a patent</option>
+            <option value="20">Sequence</option>
+            <option value="21">Device</option>
+            <option value="22">Storage / Preparation</option>
+        </center></select></center>
+    </div>
+<div class="row">
+    <div class="choose box10">Click for different patent classes!</div>
+    <div class="patent_20 box10"><p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:20.0pt;font-family:Quicksand">SEQUENCE<o:p></o:p></span></p>
+<p class="MsoNormal"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+<div style="overflow-x:auto;">
+<table class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
+ <tbody><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:36.55pt">
+  <td style="border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
+  background:#FAD990;padding:0cm 5.4pt 0cm 5.4pt;height:36.55pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><br>PRODUCT NAME<o:p></o:p></span></b></p>
+  </td>
+  <td style="border:solid windowtext 1.0pt;border-left:none;mso-border-left-alt:
+  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;background:#FAD990;
+  padding:0cm 5.4pt 0cm 5.4pt;height:36.55pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><br>PRODUCT CODE<o:p></o:p></span></b></p>
+  </td>
+  <td style="border:solid windowtext 1.0pt;border-left:none;mso-border-left-alt:
+  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;background:#FAD990;
+  padding:0cm 5.4pt 0cm 5.4pt;height:36.55pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><br>PATENTS<o:p></o:p></span></b></p>
+  </td>
+  <td style="border:solid windowtext 1.0pt;border-left:none;mso-border-left-alt:
+  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;background:#FAD990;
+  padding:0cm 5.4pt 0cm 5.4pt;height:36.55pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></b></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1">NATURE OF CLAIM /
+  JUSTIFICATION OF DIFFERENCE<o:p></o:p></span></b></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></b></p>
+  </td>
+  <td style="border:solid windowtext 1.0pt;border-left:none;mso-border-left-alt:
+  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;background:#FAD990;
+  padding:0cm 5.4pt 0cm 5.4pt;height:36.55pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><br>Y/N<o:p></o:p></span></b></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:1;height:40.7pt">
+  <td style="border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:
+  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;
+  height:40.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">INSULIN ASPART; INSULIN DEGLUDEC (RYZOGDEG 70/30)<o:p></o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:40.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N203313<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:40.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">5866538<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:40.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">The sequence claimed in this patent consists
+  of Asp(B28) human insulin which we don’t have. Furthermore, it involves the
+  actual preparation of the “insulin with glycerol and or mannitol and 5-100mM
+  of a halogen, including chloride and specifically <span class="SpellE">NaCl</span>.”<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">Whilst these are not relevant to us in the
+  present stages of our projects – they have implications on how we plan to
+  store the insulin in the future<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;height:40.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:2">
+  <td style="border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:
+  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">INSULIN DEGLUDEC<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">(TRESIBA)<o:p></o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N203314<o:p></o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">7615532<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  mso-bidi-font-family:Arial;color:black;mso-themecolor:text1;mso-bidi-font-weight:
+  bold"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  mso-bidi-font-family:Arial;color:black;mso-themecolor:text1;mso-bidi-font-weight:
+  bold">The sequence claimed by this patent involves a 4-amino acid linker
+  which notable involves carboxylation of at least one of the amino acids
+  present<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><b><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:
+  &quot;Times New Roman&quot;;mso-bidi-font-family:Arial;color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></b></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:3">
+  <td style="border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:
+  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">INSULIN DEGLUDEC, LIRAGLUTIDE (XULTOPHY 100/3.6)<o:p></o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N208583<o:p></o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">6268343, 6458924, 7235627, 8937042<o:p></o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">The present claim involves a GLP-1 compound
+  with an insulin peptide. GLP-1’s <span class="GramE">are</span> regulatory <span class="SpellE">insulintoprohic</span> compounds which are administered together
+  with insulin in this pharmaceutical product. Importantly, the insulin used is
+  <span class="SpellE">carboxylated</span> and with additional modifications;
+  sequence is </span><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;
+  mso-fareast-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black;
+  mso-themecolor:text1">N</span><span lang="EN-AU" style="font-size:13.0pt;
+  mso-ascii-font-family:Calibri;mso-fareast-font-family:Calibri;mso-hansi-font-family:
+  Calibri;mso-bidi-font-family:Calibri;color:black;mso-themecolor:text1">_</span><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:
+  Helvetica;mso-bidi-font-family:Helvetica;color:black;mso-themecolor:text1">B29-(N</span><span lang="EN-AU" style="font-size:13.0pt;mso-ascii-font-family:Calibri;mso-fareast-font-family:
+  Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:Calibri;
+  color:black;mso-themecolor:text1">_</span><span lang="EN-AU" style="font-size:
+.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
+  Helvetica;color:black;mso-themecolor:text1">-(COOH(CH2)14CO)-</span><span lang="EN-AU" style="font-size:13.0pt;mso-ascii-font-family:Calibri;mso-fareast-font-family:
+  Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:Calibri;
+  color:black;mso-themecolor:text1">_</span><span lang="EN-AU" style="font-size:
+.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
+  Helvetica;color:black;mso-themecolor:text1">-<span class="SpellE"><span class="GramE">Glu</span></span><span class="GramE">)desB</span>30)<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:4;height:10.7pt">
+  <td style="border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:
+  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;
+  height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">INSULIN DETEMIR RECOMBINANT (LEVEMINR / LEVIMER FLEXTOUCH)<o:p></o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N023156<o:p></o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">5750497<o:p></o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span class="SpellE"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1">Acylated</span></i></span><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"> insulin<o:p></o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">The sequence claimed involve <span class="SpellE">acylated</span> <span class="SpellE">produts</span> and do not reference to single chain insulin
+  production. These <span class="SpellE">acylations</span> are additional to
+  other modifications to the A and B chains including sequence deletions and
+  substitutions which are not present in our sequence. This includes <span class="SpellE">Gly</span>(A21), <span class="SpellE">Arg</span> (b31), <span class="SpellE">Arg</span>(B32)-human insulin.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:5;height:20.45pt">
+  <td style="border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:
+  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;
+  height:20.45pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">INSULIN GLARGINE; LIXISENATIDE (SOLIQUA 100/33)<o:p></o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:20.45pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N205692<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:20.45pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">9345750<o:p></o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:20.45pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">Long-acting formulations of insulins<o:p></o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">The insulin formulation that is covered is
+  specifically insulin glargine at a specific amount (300 U/mL) and <span class="SpellE">not</span> other compounds<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;height:20.45pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:6;mso-yfti-lastrow:yes;height:10.7pt">
+  <td style="border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:
+  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;
+  height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">INSULIN GLARGINE RECOMBINANT (APIDRA)<o:p></o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N021629<o:p></o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">6221633<o:p></o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">Novel insulin derivatives with rapid onset of action<o:p></o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">We are still squarely out of this. The primary modifications allowed
+  by this patent are human and animal insulin substitutions. However, In Claim
+- B30 is a -OH or the amino acid residue and furthermore, B1 is a
+  phenylalanine residue or a hydrogen atom and B3 is a basic amino acid.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">These do NOT cover human insulin single chains<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
+  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
+  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+</tbody></table></div></div>
+    <div class="patent_21 box10">
+		<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+		<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:20.0pt;font-family:Quicksand">DEVICE<o:p></o:p></span></p>
+		<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+<div style="overflow-x:auto;"><table class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
+ mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt">
+ <tbody><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes">
+  <td width="19%" style="width:19.76%;border:solid windowtext 1.0pt;mso-border-alt:
+  solid windowtext .5pt;background:#93BCC1;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><br>PRODUCT NAME</span></b><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
+  &quot;Times New Roman&quot;;color:black;mso-themecolor:text1"><o:p></o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#93BCC1;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><br>PRODUCT CODE</span></b><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
+  &quot;Times New Roman&quot;;color:black;mso-themecolor:text1"><o:p></o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#93BCC1;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><br>PATENTS</span></b><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
+  &quot;Times New Roman&quot;;color:black;mso-themecolor:text1"><o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#93BCC1;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></b></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1">NATURE OF CLAIM /
+  JUSTIFICATION OF DIFFERENCE<o:p></o:p></span></b></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  </td>
+  <td width="5%" style="width:5.16%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#93BCC1;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><br>Y/N</span></b><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;
+  mso-themecolor:text1"><o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:1">
+  <td width="19%" rowspan="5" style="width:19.76%;border:solid windowtext 1.0pt;
+  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">INSULIN DEGLUDEC<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">(TRESIBA)<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="11%" rowspan="5" style="width:11.9%;border-top:none;border-left:
+  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N203314<o:p></o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">6899699, 947154<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">Automatic injection device with reset feature<o:p></o:p></span></i></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:2">
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">8672898,<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">9687611<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">An automatic injection device with a top release
+  mechanism<o:p></o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:3;height:26.7pt">
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:26.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">8684969, 9486588<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:26.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">Injection device that houses torsion springs and
+  rotatable display influencing the operative manner of dosing insulin<o:p></o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:26.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:4">
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">8920383, 9132239<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">Dose mechanism for an injection device for limiting a
+  dose setting corresponding to the amount of medicament left<o:p></o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:5">
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">9108002<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">Dial down mechanism for wind-up type pens<o:p></o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:6">
+  <td width="19%" style="width:19.76%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">INSULIN DEGLUDEC, LIRAGLUTIDE (XULTOPHY 100/3.6)<o:p></o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N208583<o:p></o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">6899699, 8672898, 8684969, 9108002,
+  9132239, 9457154, 9486588, 9687611<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">Automatic injection device with reset feature<o:p></o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:7;height:10.7pt">
+  <td width="19%" rowspan="2" style="width:19.76%;border:solid windowtext 1.0pt;
+  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">INSULIN GLARGINE RECOMBINANT (LANTUS/LANTUS SOLOSTAR)<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="11%" rowspan="2" style="width:11.9%;border-top:none;border-left:
+  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N021080<o:p></o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">7918833<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">Pen-type injector with dose dial sleeve<o:p></o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:8;height:10.7pt">
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">7918833<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">Pen-type injector with dose dial sleeve<o:p></o:p></span></i></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:9;height:10.7pt">
+  <td width="19%" style="width:19.76%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">INSULIN GLARGINE RECOMBINANT (TOUJEO SOLOSTAR)<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N206538<o:p></o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">7918833<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">Pen-type injector with dose dial sleeve<o:p></o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:10;height:20.45pt">
+  <td width="19%" rowspan="2" style="width:19.76%;border:solid windowtext 1.0pt;
+  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:20.45pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">INSULIN GLARGINE; LIXISENATIDE (SOLIQUA 100/33)<o:p></o:p></span></p>
+  </td>
+  <td width="11%" rowspan="2" style="width:11.9%;border-top:none;border-left:
+  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:20.45pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N205692<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:20.45pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">8512297<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:20.45pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">Drive mechanisms suitable for use in drug delivery
+  devices<o:p></o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:20.45pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:11;height:10.7pt">
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">8556864, 8603044, 8679069, 8992486,
+  9011391, 9233211, 9408979, 9526844,<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">9533105,<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">9561331, 9604008, 9604009, 9610409, 9623189,
+  9775954<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">Pen-type injector with dose dial sleeve<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:12;height:10.7pt">
+  <td width="19%" style="width:19.76%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">INSULIN HUMAN (HUMULIN R, HUMULIN R PEN, HUMULUN 70/30, HUMULIN 70/30/
+  PEN)<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N018780<o:p></o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">7291132<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">Medication dispensing apparatus with triple screw
+  threads for mechanical advantage<o:p></o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:13;height:10.7pt">
+  <td width="19%" rowspan="2" style="width:19.76%;border:solid windowtext 1.0pt;
+  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">INSULIN LISPRO RECOMBINANT (HUMALOG KWIPEN)<o:p></o:p></span></p>
+  </td>
+  <td width="11%" rowspan="2" style="width:11.9%;border-top:none;border-left:
+  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N2057479<o:p></o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">7291132<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">Medication dispensing apparatus with triple screw
+  threads for mechanical advantage<o:p></o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:14;mso-yfti-lastrow:yes;height:10.7pt">
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">6551992<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">Biosynthetic osteogenic proteins and
+  osteogenic devices containing them<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">both devices and the actual materials - these materials have a
+  specific sequence and conformation to induce endochondral bone formation when
+  disposed within a matrix. Own insulin is not synthesised to have that purpose
+  and although it does have six cysteine residues – the patent covers a very specific
+  sequence that is longer than our product. <span class="GramE">Furthermore</span>
+  this patent is only relevant to a pair of polypeptides which is unlikely our
+  single chain, <span class="SpellE">Winsulin</span>.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+</tbody></table></div>
+    </div>
+    <div class="patent_22 box10">
+    	<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+    	<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:20.0pt;font-family:Quicksand">PREPARATION / STORAGE<o:p></o:p></span></p>
+    	<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+    	<div style="overflow-x:auto;"><table class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
+ mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt">
+ <tbody><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:26.1pt">
+  <td width="19%" style="width:19.76%;border:solid windowtext 1.0pt;mso-border-alt:
+  solid windowtext .5pt;background:#9EA6EA;padding:0cm 5.4pt 0cm 5.4pt;
+  height:26.1pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><br>PRODUCT NAME<o:p></o:p></span></b></p>
+  </td>
+  <td width="11%" style="width:11.9%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#9EA6EA;padding:0cm 5.4pt 0cm 5.4pt;height:26.1pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><br>PRODUCT CODE<o:p></o:p></span></b></p>
+  </td>
+  <td width="11%" style="width:11.9%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#9EA6EA;padding:0cm 5.4pt 0cm 5.4pt;height:26.1pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><br>PATENTS<o:p></o:p></span></b></p>
+  </td>
+  <td width="51%" style="width:51.28%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#9EA6EA;padding:0cm 5.4pt 0cm 5.4pt;height:26.1pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></b></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1">NATURE OF CLAIM /
+  JUSTIFICATION OF DIFFERENCE<o:p></o:p></span></b></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></b></p>
+  </td>
+  <td width="5%" style="width:5.16%;border:solid windowtext 1.0pt;border-left:
+  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  background:#9EA6EA;padding:0cm 5.4pt 0cm 5.4pt;height:26.1pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:14.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><br>Y/N<o:p></o:p></span></b></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:1;height:40.7pt">
+  <td width="19%" style="width:19.76%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:40.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">INSULIN ASPART; INSULIN DEGLUDEC (RYZOGDEG 70/30)<o:p></o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:40.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N203313<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:40.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">5866538<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:40.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">The sequence claimed in this patent consists
+  of Asp(B28) human insulin which we don’t have. Furthermore, it involves the
+  actual preparation of the “insulin with glycerol and or mannitol and 5-100mM
+  of a halogen, including chloride and specifically <span class="SpellE">NaCl</span>.”<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">Whilst these are not relevant to us in the
+  present stages of our projects – they have implications on how we plan to
+  store the insulin in the future<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:40.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:2;height:10.7pt">
+  <td width="19%" rowspan="2" style="width:19.76%;border:solid windowtext 1.0pt;
+  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">INSULIN GLARGINE RECOMBINANT (LANTUS/LANTUS SOLOSTAR)<o:p></o:p></span></p>
+  </td>
+  <td width="11%" rowspan="2" style="width:11.9%;border-top:none;border-left:
+  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N021080<o:p></o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">7476652<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">Acidic insulin preparations with improved stability<o:p></o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:3;height:10.7pt">
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">7713930<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">Similar to above – this involves a storage
+  patent where a specific human insulin construct (glargine<span class="GramE">),is</span>
+  preserved in <span class="SpellE">polysorbate</span> 20 and <span class="SpellE">polysorbate</span>
+; with at least one preservative and water and a specific acidic <span class="SpellE">pH.</span><o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">Again, this is an important consideration when
+  it comes to the <span class="GramE">long term</span> storage of our insulin and
+  its preparation.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:4;height:10.7pt">
+  <td width="19%" style="width:19.76%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">INSULIN GLARGINE RECOMBINANT (APIDRA)<o:p></o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N021629<o:p></o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">6960561, 7452860, 7696162<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">Insulin preparations, which do not contain any zinc or
+  only a small quantity of zinc and which have an improved stability<o:p></o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">A formulation comprising at least one
+  insulin <span class="SpellE">analog</span>; at least one surfactant; optionally
+  at least one preservative; and optionally at least one of an <span class="SpellE">isotonicizing</span> agent, a buffer, and an excipient, wherein
+  the pharmaceutical formulation is free from or contains less than 0.4% by
+  weight of zinc based on the insulin content of the formulation.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">Importantly, our insulin (at the stage of
+  our experimental work are currently left in storage buffer<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1"><o:p>&nbsp;</o:p></span></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+ <tr style="mso-yfti-irow:5;mso-yfti-lastrow:yes;height:10.7pt">
+  <td width="19%" style="width:19.76%;border:solid windowtext 1.0pt;border-top:
+  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
+  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">INSULIN LISPRO RECOMBINANT (HUMALOG KWIPEN)<o:p></o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">N2057479<o:p></o:p></span></p>
+  </td>
+  <td width="11%" style="width:11.9%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">6034054<o:p></o:p></span></p>
+  </td>
+  <td width="51%" style="width:51.28%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
+  mso-themecolor:text1">STABLE INSULIN FORMULATIONS<o:p></o:p></span></i></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">The stable insulin formulation claimed by
+  this patent involves claim for a stable insulin solution with a <br>
+  <span class="SpellE">i</span>) physiologically tolerated buffer from the group
+  of TRIS and arginine, and a<br>
+  ii) monomeric insulin analogue with human insulin that has a modified B28
+  position and a modified B29 lysine or proline.<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
+  color:black;mso-themecolor:text1">Our sequence does not fall under these
+  requirements in terms of modification and this patent thus would not affect
+  us<o:p></o:p></span></p>
+  <p class="MsoNormal" align="center" style="text-align:center"><i style="mso-bidi-font-style:normal"><span lang="EN-AU" style="font-size:13.0pt;
+  font-family:Quicksand;color:black;mso-themecolor:text1"><o:p>&nbsp;</o:p></span></i></p>
+  </td>
+  <td width="5%" style="width:5.16%;border-top:none;border-left:none;
+  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
+  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
+  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
+  height:10.7pt">
+  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
+  text1">N<o:p></o:p></span></p>
+  </td>
+ </tr>
+</tbody></table></div>
+	</div>
+	<div class="row" style="height:10vh;"></div>
+</div>
+<div class = "row">
+</div>
+</div>
 </body>
 </html>
 {{:Team:Sydney_Australia/templates/Footer}}

Difference between revisions of "Team:Sydney Australia/Patent Law"

Latest revision as of 22:35, 22 November 2017

Aim

How to read a patent

After our chat with Uppsala (check it out in collaborations), our team realised that patents are a very poorly understood area, particularly for young aspiring scientists with new and challenging ideas. With a resident legal student in our team - we created a quick checklist on How to read a patent

KEY CONSIDERATIONS

1. Patents give an exclusive commercial right to the invention aka. a monopoly 2. The "claims" of a patent, detail what is covered by the patent. 3. If it is NOT in the patent; it is NOT patentable.

And it is with this checklist that we approached the analysis of a wide range of patents below.

1. Single Chain Insulin Patents

HELP RUBY HELP RUBY HELP RUBY

2. Method Patents

relatively important PATENT STUFF

3. Orange Book/FDA

Search Method

All 101 patents were collated it in an excel data table (right: screenshot of excel data sheet) and formatted with Y/N based on their expiry date. We then picked out all the patents (green) in force and ordered them by their relevant associated patents and their associated claims.

Patent Categories

1. Patents give an exclusive commercial right to the invention aka. a monopoly

2. The "claims" of a patent, detail what is covered by the patent.

3. If it is NOT in the patent; it is NOT patentable.